Market News AIOpen the app

Kyntra Bio, Inc. has been told it might be removed from Nasdaq for not following the rules.

TroubleRead the original at SEC EDGAR
Bad for KYNB

Kyntra Bio has not met Nasdaq's listing tests, and staff has decided to delist its stock. A hearing lets trading continue for now, but Nasdaq may refuse more time or the company may fail to meet the rules.

KYNB · Kyntra Bio, Inc.

AI read · Bad for KYNB

The AI's read

That puts Kyntra Bio at risk of losing its place on Nasdaq. The company failed the asset-and-sales test and other listing tests. A hearing pauses the suspension, so the stock can keep trading for now. Nasdaq could allow up to 180 more days, but it may refuse the request, and the company may not meet the rules.

Get alerts for KYNB

Follow Kyntra Bio, Inc. (KYNB) free. When we publish a story about it, you get the plain-English explanation as an alert.

Get alerts for KYNB
Free on the App Store and Google Play, or on the web.